Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Attracts Leading Cancer Metabolism Experts to Advisory Team

Agios Pharmaceuticals Attracts Leading Cancer Metabolism Experts to Advisory Team

November 24, 2008

Drs Chi Dang, Joshua Rabinowitz, Clary Clish, Matthew Vander Heiden and James Bradner Bring Deep Biology and Metabolomic Experience from Leading Laboratories

Cambridge, MA – November 24, 2008 – Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel
drugs in the rapidly emerging field of cancer metabolism, announced today the appointments of several leading scientific advisors:

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals Expands Into 21,000 SqFt Facility

Agios Pharmaceuticals Expands Into 21,000 SqFt Facility

November 24, 2008

Creates Largest Research Laboratory Dedicated to Cancer Metabolism

Cambridge, MA – November 24, 2008 – Agios Pharmaceuticals, the first biopharmaceutical company focused on discovering and developing novel drugs in the rapidly emerging field of cancer metabolism, announced today that it has leased a 21,000 square-foot facility in Cambridge. This new facility creates the world’s largest laboratory dedicated to cancer metabolism research.

Ze-gen, Inc.

Terry Newendorp Joins Ze-gen’s Board of Directors

Terry Newendorp Joins Ze-gen’s Board of Directors

December 18, 2008

Boston, MA – December 18, 2008 Ze-gen, Inc., a clean energy company providing advanced gasification technology to convert waste streams into synthesis gas, is pleased to announce the addition of Terry Newendorp to its Board of Directors.

Helicos BioSciences Corporation

Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

Helicos BioSciences Corporation Announces Pricing of Common Stock and Warrant Private Placement

December 19, 2008

CAMBRIDGE, Mass., Dec 19, 2008 (BUSINESS WIRE) -- Helicos BioSciences Corporation (NASDAQ: HLCS), a life science company focused on innovative genetic analysis technologies for the research, drug discovery, and diagnostic markets, today announced that it has entered into a definitive agreement with certain investors to raise approximately $18.6 million in gross proceeds in a private placement through the sale of shares of its common stock and warrants.

Ze-gen, Inc.

Ze-gen Secures $20 Million in Funding to Deploy Technology

Ze-gen Secures $20 Million in Funding to Deploy Technology

January 13, 2009

Boston, MA – January 13, 2009 Ze-gen, Inc., which has developed commercially viable gasification technology for converting waste streams into synthesis gas, today announced that it has raised $20 million in Series B financing. The funds will be used to commercially deploy Ze-gen's technology.

Helicos BioSciences Corporation

Helicos Announces Improved Performance of Its HeliScope(TM) Single Molecule Sequencer

Helicos Announces Improved Performance of Its HeliScope(TM) Single Molecule Sequencer

February 4, 2009

30GB of High-Quality Data at 150MB per Hour Throughput Equivalent to 5 to 10 Human Genomes is Industry Best

Black Duck Software, Inc.

Black Duck Software Closes $9.5 Million in Financing

Black Duck Software Closes $9.5 Million in Financing

February 9, 2009

Capping year of solid growth, company will use funds for product enhancements and international expansion

Black Duck Software, Inc.

Software Industry Veteran Tim Yeaton Named New CEO of Black Duck Software

Software Industry Veteran Tim Yeaton Named New CEO of Black Duck Software

February 10, 2009

Track record in open source software, successful partnerships and acquisitions strengthens Black Duck leadership position

Oasys Water, Inc.

Oasys Closes $10 Million Financing

Oasys Closes $10 Million Financing

February 17, 2009

Developing ultra-low cost seawater desalination and water treatment

Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Closes $15.1M Series B Financing

Selecta Biosciences, Inc. Closes $15.1M Series B Financing

February 25, 2009

WATERTOWN, Mass.--(BUSINESS WIRE)--Selecta Biosciences, Inc., a privately held biopharmaceutical company developing immunomodulatory nanoparticles for the treatment and prevention of human diseases, announced today that it has secured a $15.1M Series B financing. Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and Professor Timothy A. Springer. “I am pleased by the strength of our investors whose track record of creating successful companies is a loud validation of our team, technology platform, and product opportunities” said Dr.